COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study

Condition:   Chronic Migraine, Headache Intervention:   Drug: Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL) Sponsor:   Chicago Headache Center & Research Institute Recruiting

Source: ClinicalTrials.gov - February 13, 2023 Category: Research Source Type: clinical trials